Exploiting structural information in patent specifications for key compound prediction

Journal of Chemical Information and Modeling

Volumn 52, Issue 6, 2012, Pages 1480-1489

  Tyrchan, Christian ^a   Boström, Jonas ^a   Giordanetto, Fabrizio ^a   Winter, Jon ^b   Muresan, Sorel ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ANALYSIS; FORECASTING; INFORMATION USE; PATENTS AND INVENTIONS; SCAFFOLDS; SPECIFICATIONS; TEXT MINING;

AUTOMATIC PREDICTION; INFORMATION SOURCES; PATENT APPLICATIONS; PATENT SPECIFICATION; PREDICTION ACCURACY; SIMILARITY MEASURE; STRUCTURAL FEATURE; STRUCTURAL INFORMATION;

STRUCTURAL ANALYSIS;

ARTICLE; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; PATENT;

DRUG DISCOVERY; MOLECULAR STRUCTURE; PATENTS AS TOPIC;

EID: 84862861641     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci3001293     Document Type: Article

References (35)

1. Hattori, K.; Wakabayashi, H.; Tamaki, K. Predicting key example compounds in competitors' patent applications using structural information alone J. Chem. Inf. Model. 2008, 48, 135-142
2. Engel, T. Basic overview of chemoinformatics J. Chem. Inf. Model. 2006, 46, 2267-2277
3. Southan, C.; Varkonyi, P.; Muresan, S. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds. J. Cheminf. [Online] 2009, 1, Article 10. http://www.jcheminf.com/ content/1/1/10 (accessed October 31, 2011).
4. Bachrach, S. Chemistry publication-making the revolution. J. Cheminf. [Online] 2009, 1, Article 2. http://www.jcheminf.com/content/1/1/2 (accessed October 31, 2011).
5. DiMasi, J. A.; Faden, L. B. Competitiveness in follow-on drug R&D: A race or imitation? Nat. Rev. Drug Discovery 2011, 10, 23-27
6. Trippe, A. J. Patinformatics: Tasks to tools World Pat. Inf. 2003, 25, 211-221
7. Bonino, D.; Ciaramella, A.; Corno, F. Review of the state-of-the-art in patent information and forthcoming evolutions in intelligent patent informatics World Pat. Inf. 2010, 32, 30-38
8. Moehrle, M. G.; Walter, L.; Bergmann, I.; Bobe, S.; Skrzipale, S. Patinformatics as a business process: A guideline through patent research tasks and tools World Pat. Inf. 2010, 32, 291-299
9. Dou, H. J.-M. Benchmarking R&D and companies through patent analysis using free databases and special software: A tool to improve innovative thinking World Pat. Inf. 2004, 26, 297-309
10. Fattori, M.; Pedrazzi, G.; Turra, R. Text mining applied to patent mapping: A practical business case World Pat. Inf. 2003, 25, 335-342
11. Kim, Y. G.; Suh, J. H.; Park, S. C. Visualization of patent analysis for emerging technology Expert Syst. Appl. 2008, 34, 1804-1812
12. SciFinder. http://www.cas.org/products/sfacad/index.html (accessed October 31, 2011); STN. http://www.cas.org/products/stnfamily/index.html (accessed October 31, 2011).
13. Kaback, S. M. What is in a patent? Information: But can I find it? J. Chem. Inf. Comput. Sci. 1984, 24, 159-163
14. Kaback, S. M. A patent searcher's personal chronicle: 40 years in the evolution of a profession J. Chem. Inf. Comput. Sci. 2002, 42, 137-142
15. Banville, D. L. Mining chemical structural information from the drug literature Drug Discovery Today 2006, 11, 35-42
16. CAS databases. http://www.cas.org/expertise/cascontent/index.html (accessed October 31, 2011).
17. Thomson Reuters Pharma. http://thomsonreuters.com/products-services/ science/science-products/a-z/thomson-pharma/ (accessed October 31, 2011).
18. GOSTAR. http://www.gostardb.com/gostar/loginEntry.do (accessed October 31, 2011).
19. SureChem. http://www.surechem.org (accessed October 31, 2011).
20. Spangler, S.; Ying, C.; Kreulen, J.; Boyer, S.; Griffin, T.; Alba, A.; Kato, L.; Lelescu, A.; Yan, S. Exploratory analytics on patent data sets using the SIMPLE platform World Pat. Inf. 2011, 33, 328-339
21. Muresan, S.; Petrov, P.; Southan, C.; Kjellberg, M. J.; Kogej, T.; Tyrchan, C.; Varkonyi, P.; Xie, P. H. Making every SAR point count: The development of Chemistry Connect for the large-scale integration of structure and bioactivity data Drug Discovery Today 2011, 16, 1019-1030
22. Lepp, Z.; Huang, C.; Okada, T. Finding key members in compound libraries by analyzing networks of molecules assembled by structural similarity J. Chem. Inf. Model. 2009, 49, 2429-2443
23. European Patent Convention. Article 100. http://www.epo.org/law-practice/ legal-texts/html/epc/2010/e/ar100.html (accessed October 31, 2011); Article 138. http://www.epo.org/law-practice/legal-texts/html/epc/2010/e/ar138.html (accessed October 31, 2011).
24. Example of patent invalidated by the US courts for failure to comply with the best mode requirement. http://www.cafc.uscourts.gov/images/stories/ opinions-orders/09-1081.pdf (accessed October 31, 2011).
25. GVKBIO Drug Database. http://www.gvkbio.com/database-pdf/Drug.pdf (accessed October 31, 2011).
26. Pipeline Pilot. http://accelrys.com/products/pipeline-pilot/ (accessed October 31, 2011).
27. Boström, J.; Hogner, A.; Schmitt, S. Do structurally similar ligands bind in a similar fashion? J. Med. Chem. 2006, 49, 6716-6725
28. Hariharan, R.; Janakiraman, A.; Nilakantan, R.; Singh, B.; Varghese, S.; Landrum, G.; Schuffenhauer, A. MultiMCS: A fast algorithm for the maximum common substructure problem on multiple molecules J. Chem. Inf. Model. 2011, 51, 788-806
29. OEChem TK. http://www.eyesopen.com/oechem-tk (accessed October 31, 2011).
30. Rabal, O.; Urbano-Cuadrado, M.; Oyarzabal, J. Computational medicinal chemistry in fragment-based drug discovery: What, how and when Future Med. Chem. 2011, 3, 95-134
31. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 1996, 39, 2887-2893
32. Simmons, E. S. Markush structure searching over the years World Pat. Inf. 2003, 25, 195-202
33. With the benefit of hindsight, it is now apparent that example 13 in WO2006021884, which was identified as the best mode compound by FOG analysis, is in fact crizotinib (Xalkori), Pfizer's anaplastic lymphoma kinase/c-Met inhibitor, which was launched as a treatment for non-small cell lung carcinoma in 2011.
34. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
35. Synthesis and biological testing information for compound 3 has been reported in patent WO2009024825.